Volume and location of bone regeneration after autologous expanded mesenchymal stromal cells in hip osteonecrosis: a pilot study. Issue 12 (14th December 2022)

• Record Type: Journal Article
• Authors: Gómez-Barrena, Enrique; Padilla-Eguiluz, Norma-Griset; López-Marfil, Marta; Ruiz de la Reina, Raquel
• Is Part Of: Bone & joint research. Volume 11:Issue 12(2022)
• Page Start: 881
• Page End: 889
• Publication Date: 2022-12-14
• Subjects: Femoral head osteonecrosis -- Mesenchymal stromal cell -- Bone regeneration -- Osteonecrosis volume -- Cell therapy efficacy -- mesenchymal stromal cells -- hip osteonecrosis -- femoral heads -- lesions -- cell therapy -- clinical trial -- MRI -- total hip arthroplasty (THA) -- bone marrow; Musculoskeletal system -- Periodicals; 573.705
• DOI: 10.1302/2046-3758.1112.BJR-2022-0152.R1
• Languages: English
• ISSNs: 2046-3758

Abstract

Abstract : Aims: Successful cell therapy in hip osteonecrosis (ON) may help to avoid ON progression or total hip arthroplasty (THA), but the achieved bone regeneration is unclear. The aim of this study was to evaluate amount and location of bone regeneration obtained after surgical injection of expanded autologous mesenchymal stromal cells from the bone marrow (BM-hMSCs). Methods: A total of 20 patients with small and medium-size symptomatic stage II femoral head ON treated with 140 million BM-hMSCs through percutaneous forage in the EudraCT 2012-002010-39 clinical trial were retrospectively evaluated through preoperative and postoperative (three and 12 months) MRI. Then, 3D reconstruction of the original lesion and the observed postoperative residual damage after bone regeneration were analyzed and compared per group based on treatment efficacy. Results: The mean preoperative lesion volume was 18.7% (SD 10.2%) of the femoral head. This reduced to 11.6% (SD 7.5%) after three months (p = 0.015) and 3.7% (SD 3%) after one year (p < 0.001). Bone regeneration in healed cases represented a mean 81.2% (SD 13.8%) of the initial lesion volume at one year. Non-healed cases (n = 1 stage progression; n = 3 THAs) still showed bone regeneration but this did not effectively decrease the ON volume. A lesion size under mean 10% (SD 6%) of the femoral head at three months predicted no ON stage progression at one year. Regeneration in the lateral femoral head (C2 under Japanese Investigation Committee (JCI) classification) and in the central and posterior regions of the head was predominant in cases without ON progression. Conclusion: Bone regeneration was observed in osteonecrotic femoral heads three months after expanded autologous BM-hMSC injection, and the volume and location of regeneration indicated the success of the therapy. Cite this article: Bone Joint Res 2022;11(12):881–889.